Predictors of the Development of Major Adverse Cardiac Events following Percutaneous Coronary Intervention

被引:0
|
作者
Azaza, Nouha [1 ]
Baslaib, Fahad O. [1 ]
Al Rishani, Akram [1 ]
Ahmed, Mariam [1 ]
Al-Zainal, Jumana [1 ]
Aboalela, Mohamed [1 ]
Gargousa, Marian [1 ]
Abdalla, Geili [1 ]
Shah, Nadim [1 ]
机构
[1] Rashid Hosp, Cardiol Dept, Dubai Hlth Author, Dubai, U Arab Emirates
来源
DUBAI MEDICAL JOURNAL | 2022年 / 5卷 / 02期
关键词
Coronary artery disease; Percutaneous coronary intervention; Predictors of major adverse cardiac events; Cardiogenic shock; Diabetes; Myocardial infarction; Risk factors; CARDIOGENIC-SHOCK; DISEASE; METAANALYSIS; ASSOCIATION; MORTALITY;
D O I
10.1159/000522481
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Coronary artery disease remains the greatest cause of morbidity and mortality worldwide despite the growing access to percutaneous coronary intervention (PCI). Data regarding the factors predicting the development of major adverse cardiac events (MACE) in patients undergoing PCI are, however, lacking in the gulf region. In this study, we analyze demographics and risk profile of all patients undergoing PCI in a tertiary cardiovascular center located in Dubai - UAE. In our study, we aimed to analyze the risk profile of all patients undergoing PCI and determine the independent predictors of MACE. Methods: Data were collected prospectively on all patients who underwent PCI in our hospital between September 2017 and September 2018. Patients aged 18 years and above were included in the study and there were no exclusion criteria. The definition of MACE was a composite of death, in-hospital recurrent myocardial infarction (MI), in-hospital target vessel revascularization (TVR), and stroke. The patients' characteristics, risk factor, and demographics were analyzed to identify the predictors of MACE using logistic regression model which is presented in odds ratio. Results: Data were available for 789 patients. Of these, 741 (94%) were male. The mean age was 52 +/- 11 years. Twenty-two (3%) patients died, 7 (1%) had an in-hospital recurrent MI, 6 (1%) had in-hospital TVR, and 1 (0.1%) had a stroke. Of the patients who died, 16 (73%) patients presented with cardiogenic shock. Major adverse cardiovascular events occurred in 29 (3.7%) patients. In the multivariable regression model, only cardiogenic shock (odds ratio [OR] = 32.43) and the presence of diabetes mellitus (OR = 3.36) were predictors of MACE. Conclusion: Our study showed that cardiogenic shock and diabetes mellitus are the independent predictors of MACE in patients undergoing PCI.
引用
收藏
页码:117 / 121
页数:5
相关论文
共 50 条
  • [21] Initial SYNTAX Score Predicts Major Adverse Cardiac Events After Primary Percutaneous Coronary Intervention
    Brown, Adam J.
    McCormick, Liam M.
    Gajendragadkar, Parag R.
    Hoole, Stephen P.
    West, Nick E. J.
    ANGIOLOGY, 2014, 65 (05) : 408 - 412
  • [22] Machine Learning for Predicting Major Adverse Cardiac Events in Percutaneous Coronary Intervention of Coronary Artery Chronic Total Occlusion
    Karacsonyi, Judit
    Stanberry, Larissa
    Bergstedt, Seth
    Rempakos, Athanasios
    Kostantinis, Spyridon
    Simsek, Bahadir
    Alexandrou, Michaella
    Allana, Salman
    Al-Ogaili, Ahmed
    Alaswad, Khaldoon
    Krestyaninov, Oleg
    Karmpaliotis, Dimitri
    Kirtane, Ajay
    McEntegart, Margaret
    Khatri, Jaikirshan
    Jaffer, Farouc
    Poommipanit, Paul
    Choi, James
    Gorgulu, Sevket
    Jaber, Wissam
    Rinfret, Stephane
    ElGuindy, Ahmed
    Rafeh, Nidal Abi
    Goktekin, Omer
    Ungi, Imre
    Azzalini, Lorenzo
    Rangan, Bavana
    Mastrodemos, Olga
    Sandoval, Yader
    Burke, M. Nicholas
    Brilakis, Emmanouil
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 82 (17) : B244 - B244
  • [23] What truly drives the significant reduction in major adverse cardiac events after switching to electronic cigarettes following percutaneous coronary intervention?
    Zhao, Yuqin
    Sun, Jun
    Lv, Xiaolei
    EUROPEAN HEART JOURNAL, 2025, 46 (10) : 981 - 981
  • [24] Evaluation of Bivalirudin-Associated Major Adverse Cardiac and Hemorrhagic Events in Acute Coronary Syndrome Patients on Chronic Dialysis Following Percutaneous Coronary Intervention
    Fu, Dongliang
    Liu, Mengru
    Gao, Tong
    Li, Chunyan
    Liao, Jiangquan
    Shao, Mingjing
    Xiao, Xiang
    Yang, Peng
    Li, Xianlun
    Jiang, Hong
    JOURNAL OF INVASIVE CARDIOLOGY, 2021, 33 (11): : E877 - E883
  • [25] Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention
    Chen, Zhihao
    Jiang, Chaohui
    Qu, Huimin
    Liang, Shuang
    Yang, Jian
    Wu, Hui
    He, Chao
    Wang, Xinan
    ARCHIVES OF MEDICAL SCIENCE, 2019, 15 (06) : 1375 - 1380
  • [26] Major adverse cardiac and cerebral events after percutaneous coronary intervention. A real world multicentre registry
    Livarek, B
    Lefevre, T
    Fosse, S
    EUROPEAN HEART JOURNAL, 2003, 24 : 583 - 583
  • [27] Stratification Analysis of Statin Effect on Major Adverse Cardiac Events After Percutaneous Coronary Intervention in Patients on Hemodialysis
    Horikoshi, Takeo
    Nakamura, Takamitsu
    Yoshizaki, Toru
    Nakamura, Jun
    Makino, Aritaka
    Saito, Yukio
    Obata, Jun-ei
    Sawanobori, Takao
    Takano, Hajime
    Umetani, Ken
    Watanabe, Akinori
    Asakawa, Tetsuya
    Kugiyama, Kiyotaka
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2022, 79 (02) : 168 - 176
  • [28] The problem with composite end points in cardiovascular studies - The story of major adverse cardiac events and percutaneous coronary intervention
    Kip, Kevin E.
    Hollabaugh, Kim
    Marroquin, Oscar C.
    Williams, David O.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (07) : 701 - 707
  • [29] Prognostic role of apolipoproteins on long-term major adverse cardiac events after percutaneous coronary intervention
    Kawahara, Hiroshi
    Endo, Akihiro
    Uchida, Kazuhiko
    Tanabe, Kazuaki
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2024, 61 : 85 - 92
  • [30] Effect of postmenopausal hormone therapy on major adverse cardiac events after percutaneous coronary intervention: The HERS trial
    Khan, MA
    Shlipak, MG
    Liu, MW
    Rogers, WJ
    Lin, F
    Hlatky, MA
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 56A - 56A